Skip to main content
Fig. 6 | Journal of Nanobiotechnology

Fig. 6

From: VEGFR2 targeted microbubble-based ultrasound molecular imaging improving the diagnostic sensitivity of microinvasive cervical cancer

Fig. 6

Biocompatibility of MBs in vivo. (A) One day after injection of 100 times the conventional dose of MBCon, MBVEGFR2 and PBS, representative histopathologic images of major organs (from left to right: heart, lung, liver, kidney, spleen) with H&E staining. (B) and (C) One day after injection of 100 times the conventional dose of MBCon, MBVEGFR2 and PBS, serum biochemical values, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN) and creatinine (Cr). (ns = nonsignificant)

Back to article page